Goldman Sachs’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $107M | Sell |
4,155,895
-251,360
| -6% | -$5.16M | 0.01% | 1175 |
|
|
2026
Q1 | $84.6M | Buy |
4,407,255
+571,452
| +15% | +$11.4M | 0.01% | 1157 |
|
|
2025
Q4 | $63.3M | Buy |
3,835,803
+1,672,098
| +77% | +$28.2M | 0.01% | 1311 |
|
|
2025
Q3 | $31.4M | Buy |
2,163,705
+298,381
| +16% | +$4.29M | ﹤0.01% | 1826 |
|
|
2025
Q2 | $26.1M | Buy |
1,865,324
+193,246
| +12% | +$2.72M | ﹤0.01% | 1886 |
|
|
2025
Q1 | $22.7M | Buy |
1,672,078
+614,555
| +58% | +$11.8M | ﹤0.01% | 1913 |
|
|
2024
Q4 | $21.6M | Sell |
1,057,523
-310,298
| -23% | -$7.94M | ﹤0.01% | 2056 |
|
|
2024
Q3 | $39.8M | Buy |
1,367,821
+148,896
| +12% | +$3.69M | 0.01% | 1434 |
|
|
2024
Q2 | $28.3M | Buy |
1,218,925
+314,564
| +35% | +$6.04M | ﹤0.01% | 1590 |
|
|
2024
Q1 | $18.6M | Buy |
904,361
+510,556
| +130% | +$9.6M | ﹤0.01% | 1904 |
|
|
2023
Q4 | $8.45M | Sell |
393,805
-13,588
| -3% | -$269K | ﹤0.01% | 2684 |
|
|
2023
Q3 | $8.4M | Sell |
407,393
-237,521
| -37% | -$6.02M | ﹤0.01% | 2536 |
|
|
2023
Q2 | $19M | Buy |
644,914
+72,071
| +13% | +$2.03M | ﹤0.01% | 1895 |
|
|
2023
Q1 | $13.2M | Sell |
572,843
-198,609
| -26% | -$5.47M | ﹤0.01% | 2171 |
|
|
2022
Q4 | $21.5M | Buy |
771,452
+43,180
| +6% | +$1.28M | 0.01% | 1886 |
|
|
2022
Q3 | $22.4M | Buy |
728,272
+307,530
| +73% | +$10M | 0.01% | 1767 |
|
|
2022
Q2 | $12.4M | Buy |
420,742
+14,514
| +4% | +$380K | ﹤0.01% | 2300 |
|
|
2022
Q1 | $13.1M | Sell |
406,228
-4,536
| -1% | -$156K | ﹤0.01% | 2423 |
|
|
2021
Q4 | $18.3M | Sell |
410,764
-645,794
| -61% | -$30.6M | ﹤0.01% | 2186 |
|
|
2021
Q3 | $53.3M | Buy |
1,056,558
+468,740
| +80% | +$26.4M | 0.01% | 1239 |
|
|
2021
Q2 | $46.1M | Sell |
587,818
-60,033
| -9% | -$3.71M | 0.01% | 1332 |
|
|
2021
Q1 | $37M | Sell |
647,851
-54,543
| -8% | -$3.65M | 0.01% | 1413 |
|
|
2020
Q4 | $58.8M | Buy |
702,394
+196,852
| +39% | +$11.9M | 0.02% | 998 |
|
|
2020
Q3 | $18.1M | Buy |
505,542
+277,733
| +122% | +$8.36M | 0.01% | 1814 |
|
|
2020
Q2 | $5.51M | Buy |
227,809
+96,444
| +73% | +$2.27M | ﹤0.01% | 2734 |
|
|
2020
Q1 | $2.3M | Buy |
131,365
+30,578
| +30% | +$638K | ﹤0.01% | 3200 |
|
|
2019
Q4 | $1.76M | Sell |
100,787
-3,300
| -3% | -$54.9K | ﹤0.01% | 3738 |
|
|
2019
Q3 | $1.59M | Buy |
104,087
+8,029
| +8% | +$153K | ﹤0.01% | 3689 |
|
|
2019
Q2 | $1.99M | Sell |
96,058
-11,236
| -10% | -$252K | ﹤0.01% | 3567 |
|
|
2019
Q1 | $2.49M | Buy |
107,294
+39,016
| +57% | +$816K | ﹤0.01% | 3475 |
|
|
2018
Q4 | $1.41M | Buy |
68,278
+56,100
| +461% | +$1.02M | ﹤0.01% | 3766 |
|
|
2018
Q3 | $265K | Sell |
12,178
-41,352
| -77% | -$684K | ﹤0.01% | 4774 |
|
|
2018
Q2 | $816K | Sell |
53,530
-79,005
| -60% | -$1.49M | ﹤0.01% | 4212 |
|
|
2018
Q1 | $2.61M | Sell |
132,535
-7,441
| -5% | -$153K | ﹤0.01% | 3400 |
|
|
2017
Q4 | $2.19M | Buy |
+139,976
| New | +$2.52M | ﹤0.01% | 3720 |
|
Other funds holding DNLI
Goldman Sachs's DNLI Position: Q2 2026 in Review
Goldman Sachs reduced its Denali Therapeutics (DNLI) stake by 5.7% in Q2 2026, selling an estimated $5.16M and leaving 4,155,895 shares worth $107M. The position accounts for 0.01% of the portfolio, ranked #1175.
Goldman Sachs first reported a position in DNLI in Q4 2017 and has held it in 35 quarters since. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.
- Goldman Sachs held 4,155,895 shares of Denali Therapeutics worth $107M as of Q2 2026.
- Goldman Sachs sold 251,360 Denali Therapeutics shares in Q2 2026, an estimated $5.16M.
- Denali Therapeutics made up 0.01% of Goldman Sachs's portfolio in Q2 2026, its #1175 holding.
- Goldman Sachs first reported a position in Denali Therapeutics in Q4 2017 and has held it in 35 quarters since.
- 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.
Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.